MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Metagenomi Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$0.81+0.03 (+3.55%)
Close on Oct 19, 2026
- Market cap
- $30.57M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
16.6%
6M of 38M shares
Institutional holders
43
4 new, 8 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
2 buys · 13 sales
Net sold $9.67K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bayer HealthCare LLC | 4,050,997 | 10.80% | 13G (passive) | Sep 30, 2024 |
| Thomas Brian C. | 2,762,142 | 7.30% | 13G (passive) | Jun 30, 2026 |
| Koichiro Nakamura | 1,892,873 | 5.10% | 13G (passive) | Feb 9, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MGX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 1,077,700 | 2.85% | $1.28M | +19,756 | 0.00% |
| Renaissance Technologies LLC | 742,400 | 1.97% | $883.46K | −45,500 | 0.00% |
| Catalio Capital Management, LP | 528,993 | 1.40% | $629.50K | – | 0.12% |
| Peapod Lane Capital LLC | 525,024 | 1.39% | $624.78K | +8,263 | 0.42% |
| Two Sigma Investments, LP | 513,701 | 1.36% | $611.30K | +16,934 | 0.00% |
| Bridgeway Capital Management, LLC | 400,300 | 1.06% | $476.36K | +4,500 | 0.01% |
| Wells Fargo & Company/Mn | 379,508 | 1.00% | $451.61K | +177,370 | 0.00% |
| Geode Capital Management, LLC | 288,665 | 0.76% | $343.67K | −69,535 | 0.00% |
| Pura Vida Investments, LLC | 264,391 | 0.70% | $314.63K | – | 1.91% |
| BlackRock, Inc. | 257,631 | 0.68% | $306.58K | +27,497 | 0.00% |
| Vanguard Fiduciary Trust Co | 171,251 | 0.45% | $203.79K | +1,077 | 0.00% |
| Jacobs Levy Equity Management, Inc | 160,000 | 0.42% | $190.40K | −222,153 | 0.00% |
| State Street Corp | 119,850 | 0.32% | $142.62K | −577 | 0.00% |
| Millennium Management LLC | 114,025 | 0.30% | $135.69K | −56,079 | 0.00% |
| Man Group plc | 109,130 | 0.29% | $129.87K | +30,494 | 0.00% |
| Resolute Advisors LLC | 89,944 | 0.24% | $107.03K | – | 0.03% |
| Marquette Asset Management, LLC | 72,121 | 0.19% | $85.82K | New | 0.01% |
| Northern Trust Corp | 68,938 | 0.18% | $82.04K | −6,234 | 0.00% |
| RBF Capital, LLC | 64,021 | 0.17% | $76.19K | – | 0.00% |
| XTX Topco Ltd | 55,707 | 0.15% | $66.29K | +15,125 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 43 | 6M | 16.6% | 4 / 12 | 13 / 8 | 0M | 1M |
| Q1 2026 | 48 | 6M | 17.1% | 5 / 9 | 16 / 12 | 2M | 1M |
| Q4 2025 | 56 | 7M | 18.1% | 11 / 14 | 17 / 9 | 2M | 1M |
| Q3 2025 | 58 | 6M | 16.0% | 9 / 12 | 22 / 19 | 1M | 2M |
| Q2 2025 | 69 | 8M | 20.4% | 16 / 20 | 20 / 26 | 2M | 4M |
| Q1 2025 | 79 | 10M | 25.9% | 11 / 28 | 20 / 8 | 1M | 2M |
| Q4 2024 | 77 | 11M | 28.5% | 23 / 30 | 13 / 13 | 6M | 7M |
| Q3 2024 | 67 | 12M | 30.9% | 23 / 21 | 10 / 9 | 2M | 2M |
| Q2 2024 | 54 | 12M | 32.3% | 15 / 15 | 14 / 11 | 1M | 2M |
| Q1 2024 | 50 | 13M | 35.4% | 50 / 0 | 0 / 0 | 13M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MGX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 741,407 | 1.96% | $882.27K | 0.00% | Jun 30, 2026 |
| Ultra-Small Company Fund | 327,100 | 0.87% | $389.25K | 0.39% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 315,460 | 0.84% | $375.40K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 189,092 | 0.50% | $257.17K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 95,479 | 0.25% | $113.62K | 0.01% | Jun 30, 2026 |
| Ultra-Small Company Market Fund | 62,200 | 0.16% | $74.02K | 0.05% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 47,211 | 0.12% | $64.21K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 36,088 | 0.10% | $49.08K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 21,951 | 0.06% | $29.85K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 20,833 | 0.06% | $24.79K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 6,882 | 0.02% | $8.19K | 0.00% | Jun 30, 2026 |
| Spectrum Fund | 5,496 | 0.01% | $6.54K | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 2,600 | 0.01% | $3.09K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jian Irish | See Remarks, Director | 668,107 | 1.77% | Sep 10, 2026 |
| Matthew Wein | See Remarks | 126,133 | 0.33% | Sep 10, 2026 |
| Pamela Wapnick | Chief Financial Officer | 206,580 | 0.55% | Sep 10, 2026 |
| Sarah B. Noonberg | Chief Medical Officer | 109,135 | 0.29% | Jun 9, 2025 |
| Laurence Reid | Director | 20,000 | 0.05% | Sep 11, 2026 |
| Eric Bjerkholt | Director | – | – | Jun 11, 2026 |
| Willard H. Dere | Director | 51,275 | 0.14% | Jun 11, 2026 |
| Juergen Eckhardt | Director | – | – | Jun 11, 2026 |
| Brian C. Thomas | Director | 2,510,960 | 6.65% | Dec 8, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Laurence Reid Director | Sep 9, 2026 | Buy | +117 | $1.18 | $138 | 20,000 |
| Laurence Reid Director | Sep 9, 2026 | Buy | +19,883 | $1.17 | $23.26K | 19,883 |
| Pamela Wapnick Chief Financial Officer | Sep 8, 2026 | Sale | −1,911 | $1.16 | $2.22K | 206,580 |
| Matthew Wein See Remarks | Sep 8, 2026 | Sale | −358 | $1.16 | $415 | 126,133 |
| Jian Irish See Remarks, Director | Sep 8, 2026 | Sale | −2,140 | $1.16 | $2.48K | 375,393 |
| Matthew Wein See Remarks | Jun 5, 2026 | Sale | −558 | $1.30 | $725 | 126,491 |
| Pamela Wapnick Chief Financial Officer | Jun 5, 2026 | Sale | −2,884 | $1.30 | $3.75K | 208,491 |
| Jian Irish See Remarks, Director | Jun 5, 2026 | Sale | −3,737 | $1.30 | $4.86K | 377,533 |
| Matthew Wein See Remarks | Apr 1, 2026 | Award | +11,000 | – | – | 125,549 |
| Jian Irish See Remarks, Director | Apr 1, 2026 | Award | +46,000 | – | – | 379,770 |
| Pamela Wapnick Chief Financial Officer | Apr 1, 2026 | Award | +24,000 | – | – | 211,375 |
| Matthew Wein See Remarks | Mar 5, 2026 | Sale | −482 | $1.60 | $771 | 114,549 |
| Pamela Wapnick Chief Financial Officer | Mar 5, 2026 | Sale | −1,581 | $1.60 | $2.53K | 187,375 |
| Jian Irish Chief Executive Officer, Director | Mar 5, 2026 | Sale | −1,607 | $1.60 | $2.57K | 333,770 |
| Jian Irish Chief Executive Officer, Director | Dec 5, 2025 | Gift | −228,462 | – | – | 335,377 |
| Brian C. Thomas Director | Dec 5, 2025 | Sale | −3,830 | $1.77 | $6.78K | 2,510,960 |
| Pamela Wapnick Chief Financial Officer | Dec 5, 2025 | Sale | −1,576 | $1.77 | $2.79K | 188,956 |
| Jian Irish Chief Executive Officer, Director | Dec 5, 2025 | Sale | −1,602 | $1.77 | $2.84K | 563,839 |
| Matthew Wein See Remarks | Dec 5, 2025 | Sale | −199 | $1.77 | $352 | 115,031 |
| Jian Irish Chief Executive Officer, Director | Dec 1, 2025 | Award | +211,000 | $1.60 | $337.60K | 565,441 |
| Jian Irish Chief Executive Officer, Director | Dec 1, 2025 | Award | +37,500 | $1.60 | $60.00K | 354,441 |
| Pamela Wapnick Chief Financial Officer | Dec 1, 2025 | Award | +120,000 | $1.60 | $192.00K | 190,532 |
| Matthew Wein See Remarks | Dec 1, 2025 | Award | +96,000 | $1.60 | $153.60K | 115,230 |
| Brian C. Thomas Director | Sep 5, 2025 | Sale | −2,701 | $1.81 | $4.89K | 2,514,790 |
| Jian Irish Chief Executive Officer, Director | Sep 5, 2025 | Sale | −1,602 | $1.81 | $2.90K | 316,941 |
| Pamela Wapnick Chief Financial Officer | Sep 5, 2025 | Sale | −1,576 | $1.81 | $2.85K | 70,532 |
| Matthew Wein See Remarks | Sep 5, 2025 | Sale | −199 | $1.81 | $360 | 19,230 |
| Brian C. Thomas Chief Executive Officer, Director | Jun 6, 2025 | Sale | −10,785 | $1.75 | $18.87K | 2,517,491 |
| Pamela Wapnick Chief Financial Officer | Jun 6, 2025 | Sale | −1,576 | $1.75 | $2.76K | 72,108 |
| Jian Irish See Remarks, Director | Jun 6, 2025 | Sale | −6,390 | $1.75 | $11.18K | 315,543 |
| Matthew Wein See Remarks | Jun 6, 2025 | Sale | −199 | $1.75 | $348 | 16,693 |
| Sarah B. Noonberg Chief Medical Officer | Jun 6, 2025 | Sale | −5,239 | $1.75 | $9.17K | 109,135 |
| Pamela Wapnick Chief Financial Officer | Apr 1, 2025 | Award | +14,000 | – | – | 73,684 |
| Sarah B. Noonberg Chief Medical Officer | Apr 1, 2025 | Award | +14,000 | – | – | 114,374 |
| Brian C. Thomas Chief Executive Officer, Director | Apr 1, 2025 | Award | +32,000 | – | – | 2,528,276 |
| Matthew Wein See Remarks | Apr 1, 2025 | Award | +3,650 | – | – | 13,117 |
| Matthew Wein See Remarks | Apr 1, 2025 | Award | +3,775 | – | – | 16,892 |
| Jian Irish See Remarks, Director | Apr 1, 2025 | Award | +23,000 | – | – | 321,933 |
| Pamela Wapnick Chief Financial Officer | Mar 5, 2025 | Sale | −1,808 | $1.87 | $3.38K | 59,684 |
| Matthew Wein See Remarks | Mar 5, 2025 | Sale | −930 | $1.87 | $1.74K | 9,467 |
| Pamela Wapnick Chief Financial Officer | Dec 5, 2024 | Sale | −1,559 | $1.86 | $2.90K | 61,492 |
| Pamela Wapnick Chief Financial Officer | Sep 5, 2024 | Sale | −6,265 | $2.88 | $18.04K | 63,051 |
| Matthew Wein See Remarks | Apr 1, 2024 | Award | +10,397 | – | – | 10,397 |
| Simon Harnest See Remarks | Apr 1, 2024 | Award | +11,552 | – | – | 122,664 |
| Brian C. Thomas Chief Executive Officer, Director | Apr 1, 2024 | Award | +118,992 | – | – | 2,496,276 |
| Luis Borges Chief Scientific Officer | Apr 1, 2024 | Award | +69,316 | – | – | 69,316 |
| Simren Delaney See Remarks | Apr 1, 2024 | Award | +6,931 | – | – | 93,892 |
| Jian Irish See Remarks, Director | Apr 1, 2024 | Award | +70,471 | – | – | 298,933 |
| Sarah B. Noonberg Chief Medical Officer | Apr 1, 2024 | Award | +57,763 | – | – | 100,374 |
| Pamela Wapnick Chief Financial Officer | Apr 1, 2024 | Award | +69,316 | – | – | 69,316 |
| Holdings A/S Novo 10% owner | Feb 13, 2024 | Conversion | +839,175 | – | – | 939,175 |
| Holdings A/S Novo 10% owner | Feb 13, 2024 | Buy | +800,000 | $15.00 | $12.00M | 1,739,175 |
| World Investments B.V. Bayer 10% owner | Feb 13, 2024 | Conversion | +509,855 | – | – | 4,050,997 |
| World Investments B.V. Bayer 10% owner | Feb 13, 2024 | Conversion | +1,770,888 | – | – | 1,770,888 |
| World Investments B.V. Bayer 10% owner | Feb 13, 2024 | Conversion | +1,180,592 | – | – | 2,951,480 |
| World Investments B.V. Bayer 10% owner | Feb 13, 2024 | Conversion | +589,662 | – | – | 3,541,142 |
| Sebastian Bernales Director | Feb 13, 2024 | Conversion | +1,896,445 | – | – | 1,896,445 |
| Sebastian Bernales Director | Feb 13, 2024 | Conversion | +513,004 | – | – | 769,845 |
| Holdings A/S Novo 10% owner | Feb 9, 2024 | Buy | +100,000 | $10.25 | $1.03M | 100,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Sarah B. Noonberg FORMER OFFICER | Sep 11, 2025 | 35,832 | $68.08K | Sep 11, 2025 | STOCK AWARD |
| Bernales Sebastian Affiliate | Jul 9, 2025 | 769,845 | $1.47M | Jul 9, 2025 | Conversion of Common Units |